GENI
Genius Sports Limited
GENI trails on the overall score without a compensating advantage in the available component scores.
NFLX
Netflix, Inc.
NFLX has the edge over GENI overall, supported by stronger valuation and lower modeled downside.
GENI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Strong |
GENI's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
NFLX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
NFLX's revenue, profitability, cash flow and balance sheet are all currently healthy.
GENI PE Valuation
GENI has no meaningful PE right now: it lost money over the past year.
NFLX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 17x | $62.69 | — |
| Current | 18x | $62.69 | — |
| Cheap | 27x | $94.95 | +51% |
| Fair | 47x | $161 | +157% |
| Expensive | 81x | $281 | +348% |
Historical ranges are pointers, not guarantees.
NFLX's PE is in its cheap range at 18x. If earnings grow as analysts expect, today's price would be 17x next year's earnings.
GENI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect GENI's losses to grow, with revenue growing. However, they disagree widely on these estimates.
NFLX Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
NFLX has the edge over GENI on the outlook, with more favorable earnings and profitability expectations.
GENI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.68 | -$0.37 |
| Q1 2026 | -$0.61 | -$0.42 |
| Q4 2025 | -$0.43 | -$0.16 |
| Q3 2025 | -$0.47 | -$0.15 |
| Q2 2025 | -$0.31 | +$0.12 |
| Q1 2025 | -$0.19 | +$0.20 |
| Q4 2024 | -$0.27 | +$0.13 |
| Q3 2024 | -$0.32 | +$0.54 |
GENI is still losing money, but far less than before: $0.68 per share over the past year, against $3.94 at its worst in early 2022.
NFLX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.58 | +3.5% |
| Q3 2026 | $3.46 | +45% |
| Q2 2026 | $3.18 | +35% |
| Q1 2026 | $3.10 | +46% |
| Q4 2025 | $2.53 | +28% |
| Q3 2025 | $2.39 | +35% |
| Q2 2025 | $2.35 | +47% |
| Q1 2025 | $2.12 | +47% |
| Q4 2024 | $1.98 | +65% |
NFLX has the edge over GENI on earnings quality, reporting a profit while its opponent remains loss making.
GENI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $195.5M | +65% |
| Q1 2026 | $188M | +31% |
| Q4 2025 | $240.5M | +37% |
| Q3 2025 | $166.3M | +38% |
| Q2 2025 | $118.7M | +24% |
| Q1 2025 | $144M | +20% |
| Q4 2024 | $175.5M | +38% |
| Q3 2024 | $120.2M | +18% |
GENI has the edge over NFLX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -14% | +54 points |
| Q1 2026 | -16% | -1.6 points |
| Q4 2025 | -8.4% | -4.3 points |
| Q3 2025 | -14% | -8.8 points |
| Q2 2025 | -68% | -46 points |
| Q1 2025 | -14% | +6.1 points |
| Q4 2024 | -4.1% | +23 points |
| Q3 2024 | -5% | +3.7 points |
GENI's operating margin was −14% last quarter, up 54 points from the same quarter a year ago.
NFLX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.9B | +12% |
| Q2 2026 | $12.6B | +13% |
| Q1 2026 | $12.2B | +16% |
| Q4 2025 | $12.1B | +18% |
| Q3 2025 | $11.5B | +17% |
| Q2 2025 | $11.1B | +16% |
| Q1 2025 | $10.5B | +13% |
| Q4 2024 | $10.2B | +16% |
NFLX's revenue has grown year over year every quarter since late 2020: $12.9B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 35% | +6.4 points |
| Q2 2026 | 33% | -0.7 points |
| Q1 2026 | 32% | +0.5 points |
| Q4 2025 | 25% | +2.4 points |
| Q3 2025 | 28% | -1.4 points |
| Q2 2025 | 34% | +6.8 points |
| Q1 2025 | 32% | +3.7 points |
| Q4 2024 | 22% | +5.2 points |
NFLX has the edge over GENI on profitability, with a higher operating margin.
GENI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$87M | -$67.8M |
| Q1 2026 | -$68.2M | -$20M |
| Q4 2025 | $69.6M | -0.4% |
| Q3 2025 | $19.1M | +$41.8M |
| Q2 2025 | -$19.2M | -$16.5M |
| Q1 2025 | -$48.3M | -$21.3M |
| Q4 2024 | $69.9M | +559% |
| Q3 2024 | -$22.7M | -7493% |
GENI has burned cash in most quarters: −$66M over the past year, against −$20M the year before.
NFLX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.9B | +8.4% |
| Q2 2026 | $1.5B | -33% |
| Q1 2026 | $5.1B | +91% |
| Q4 2025 | $1.9B | +36% |
| Q3 2025 | $2.7B | +21% |
| Q2 2025 | $2.3B | +87% |
| Q1 2025 | $2.7B | +25% |
| Q4 2024 | $1.4B | -13% |
NFLX has the edge over GENI on cash generation, producing positive trailing cash flow while its opponent burns cash.
GENI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.5% | +9.5M shares |
| 1 year | +10% | +25.7M shares |
| 3 years | +34% | +70.4M shares |
| 5 years | +85% | +128M shares |
| Available history | +56% | +100M shares |
GENI has 279M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
GENI hasn't bought back shares in the past year.
NFLX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -66.2M shares |
| 1 year | -3.3% | -145M shares |
| 3 years | -6.8% | -305M shares |
| 5 years | -7.8% | -354M shares |
| Available history | -7.1% | -323M shares |
NFLX has the edge over GENI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $4.8B |
| Q2 2026 | $4.7B |
| Q1 2026 | $1.3B |
| Q4 2025 | $2.1B |
| Q3 2025 | $1.9B |
| Q2 2025 | $1.7B |
| Q1 2025 | $3.5B |
| Q4 2024 | $963.7M |
NFLX spent $12.9B buying back its own shares over the past year, up 61% from the year before.
GENI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -12.5x | Net Cash |
| Q4 2024 | -6.3x | Net Cash |
| Q1 2024 | -7.5x | Net Cash |
| Q4 2023 | -15.2x | Net Cash |
| Q1 2021 | 4.3x | High |
| Q4 2020 | 5.5x | High |
| Q3 2020 | 9.1x | High |
GENI has more cash than debt.
NFLX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.4x | Very low |
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.7x | Very low |
NFLX's net debt is less than a year of its operating earnings (EBITDA).
GENI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.6 | Neutral |
| Stochastic | 23.4 | Neutral |
GENI's weekly RSI is 46 (neutral) and its Stochastic is 23 (neutral).
NFLX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.2 | Neutral |
| Stochastic | 6.0 | Oversold |
NFLX's weekly RSI is 33 (neutral) and its Stochastic is 6 (oversold).
GENI PE vs Communication Services Sector
GENI has no meaningful PE right now: it lost money over the past year.
NFLX PE vs Communication Services Sector
| Metric | NFLX | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 16x | 9.8% above |
| PE % | 4 | 26 | 22 pts below |
NFLX is trading at 18x earnings, in line with the Communication Services sector's median of 16x.
GENI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.28 | 2.9% below |
| 20 week MA | $6.73 | 9.4% below |
| 50 week MA | $6.77 | 9.9% below |
| 100 week MA | $8.60 | 29% below |
| 200 week MA | $7.35 | 17% below |
GENI is in a downtrend: it's below all five of its weekly moving averages, and 17% below its 200-week average.
NFLX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $66.6 | 5.9% below |
| 20 week MA | $71.8 | 13% below |
| 50 week MA | $82.4 | 24% below |
| 100 week MA | $96.0 | 35% below |
| 200 week MA | $74.4 | 16% below |
NFLX is in a downtrend: it's below all five of its weekly moving averages, and 16% below its 200-week average.
GENI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $16.6 | +68% |
| 2021 | $16.6 | $7.61 | -54% |
| 2022 | $7.61 | $3.27 | -57% |
| 2023 | $3.27 | $6.18 | +89% |
| 2024 | $6.18 | $8.75 | +42% |
| 2025 | $8.75 | $10.9 | +24% |
| 2026 YTD | $10.9 | $6.10 | -44% |
GENI is down 44% so far in 2026, after finishing higher in four of the previous six years.
NFLX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $32.9 | $51.4 | +56% |
| 2021 | $51.4 | $61.4 | +19% |
| 2022 | $61.4 | $29.5 | -52% |
| 2023 | $29.5 | $48.7 | +65% |
| 2024 | $48.7 | $90.8 | +86% |
| 2025 | $90.8 | $94.5 | +4.1% |
| 2026 YTD | $94.5 | $62.7 | -34% |
NFLX has the edge over GENI on returns for 2026, with the stronger performance.